Carbonic anhydrases: novel therapeutic applications for inhibitors and activators (original) (raw)

• Scozzafava, A., Mastrolorenzo, A. & Supuran, C. T. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin. Ther. Pat. 16, 1627–1664 (2006).
  CAS Google Scholar
• Supuran, C. T., Scozzafava, A. & Conway, J. Carbonic Anhydrase — Its inhibitors and Activators 1–363 (CRC, Boca Raton, 2004).
  Google Scholar
• Supuran, C. T., Scozzafava, A. & Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 23, 146–189 (2003). A comprehensive review on the development of CAIs.
  CAS PubMed Google Scholar
• Smith, K. S. & Ferry, J. G. Prokaryotic carbonic anhydrases. FEMS Microbiol. Rev. 24, 335–366 (2000).
  CAS PubMed Google Scholar
• Thiry, A. et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 27, 566–573 (2006). An up-to-date review regarding the targeting of the tumour-associated CA IX by small-molecule inhibitors.
  CAS PubMed Google Scholar
• Stams, T. & Christianson, D. W. in The Carbonic Anhydrases — New Horizons (eds Chegwidden, W. R., Carter, N. D. & Edwards, Y. H.) 159–174 (Birkhauser, Basel, 2000).
  Google Scholar
• Pastorekova, S. et al. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 19, 199–229 (2004).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 15, 7229–7236 (2007).
  CAS PubMed Google Scholar
• Vullo, D. et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Chem. 47, 1272–1279 (2004).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 48, 7860–7866 (2005).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. DNA cloning, characterization and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 50, 381–388 (2007).
  CAS PubMed Google Scholar
• Vullo, D. et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 15, 971–976 (2005).
  CAS PubMed Google Scholar
• Nishimori, I. in Carbonic Anhydrase — Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway J.) 25–43 (CRC, Boca Raton, 2004).
  Google Scholar
• Vullo, D., et al. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 13, 1005–1009 (2003). First CA IX inhibition study reported showing the enzyme to be a druggable target.
  CAS PubMed Google Scholar
• Vullo, D. et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides — a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 15, 963–969 (2005). First CA XII inhibition study reported. This isozyme is involved in glaucoma and cancer.
  CAS PubMed Google Scholar
• Lehtonen, J. et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. 279, 2719–2727 (2004).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg. Med. Chem. Lett. 15, 3828–3833 (2005).
  CAS PubMed Google Scholar
• Alterio, V. et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 128, 8329–8335 (2006). X-ray crystal structure of a fluorescent, antitumour sulphonamide in adduct with CA II and homology modelling for the binding to CA IX. Opens new prospectives for the design of isoform-specific CAIs.
  CAS PubMed Google Scholar
• Köhler, K. et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew. Chem. Int. Ed. Engl. 46, 7697–7699 (2007).
  PubMed Google Scholar
• Supuran, C. T., Ilies M. A. & Scozzafava, A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur. J. Med. Chem. 33, 739–752 (1998).
  CAS Google Scholar
• Supuran, C. T., Scozzafava, A., Ilies M. A. & Briganti, F. Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enz. Inhib. 15, 381–401 (2000).
  CAS Google Scholar
• Scozzafava, A., Briganti, F., Ilies, M. A. & Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isozymes. J. Med. Chem. 43, 292–300 (2000). A report of membrane-impermeable CAIs, which selectively inhibit extracellular and not cytosolic isozymes.
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J. Med. Chem. 49, 7024–7031 (2006).
  CAS PubMed Google Scholar
• Saczewski, F. et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg. Med. Chem. Lett. 16, 4846–4851 (2006).
  CAS PubMed Google Scholar
• De Simone, G. et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J. Med. Chem. 49, 5544–5551 (2006).
  CAS PubMed Google Scholar
• Krungkrai, J. et al. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action? Bioorg. Med. Chem. 13, 483–489 (2005).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. DNA cloning and inhibition studies of the α-carbonic anhydrase from Helicobacter pylori: a new target for developing sulfonamide and sulfamate gastric drugs. J. Med. Chem. 49, 2117–2126 (2006).
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase inhibitors. The β-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg. Med. Chem. Lett. 17, 3585–3594 (2007). A proof-of-concept study showing that enzymes belonging to the β-CA class are also druggable targets.
  CAS PubMed Google Scholar
• Suarez Covarrubias, A. et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 280, 18782–18789 (2005).
  CAS PubMed Google Scholar
• Klengel, T. et al. Fungal adenylyl cyclase integrates CO2 sensing with cAMP signaling and virulence. Curr. Biol. 15, 2021–2026 (2005).
  CAS PubMed PubMed Central Google Scholar
• Morgensen, E.G. et al. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryot. Cell 5, 103–111 (2006).
  Google Scholar
• Bahn, Y. S. et al. Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr. Biol. 15, 2013–2020 (2005).
  CAS PubMed Google Scholar
• Soto, A. R. et al. Identification and preliminary characterization of two cDNAs encoding unique carbonic anhydrases from the marine alga Emiliania huxleyi. Appl. Environ. Microbiol. 72, 5500–5511 (2006).
  CAS PubMed PubMed Central Google Scholar
• Aguilera, J. et al. Carbonic anhydrase (Nce103p): an essential biosynthetic enzyme for growth of Saccharomyces cerevisiae at atmospheric carbon dioxide pressure. Biochem. J. 391, 311–316 (2005).
  CAS PubMed PubMed Central Google Scholar
• Supuran, C. T. & Scozzafava, A. in The Carbonic Anhydrases — New Horizons (eds Chegwidden, W. R., Carter, N. D. & Edwards, Y. H.) 197–219 (Birkhauser, Basel, 2000).
  Google Scholar
• Ilies, M. et al. Carbonic anhydrase activators. in Carbonic Anhydrase — Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 317–352 (CRC, Boca Raton, 2004).
  Google Scholar
• Briganti, F. et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 36, 10384–10392 (1997). First study characterizing CA activators by means of X-ray crsytallography.
  CAS PubMed Google Scholar
• Temperini, C. et al. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton transfer processes within the active site of an enzyme. Chemistry 12, 7057–7066 (2006).
  CAS PubMed Google Scholar
• Temperini, C. et al. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design. J. Med. Chem. 49, 3019–3027 (2006).
  CAS PubMed Google Scholar
• Sun, M.-K. & Alkon, D. L. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol. Sci. 23, 83–89 (2002).
  CAS PubMed Google Scholar
• Temperini, C. et al. Carbonic anhydrase activators: L-adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg. Med. Chem. Lett. 17, 628–635 (2007).
  CAS PubMed Google Scholar
• Splendiani, G. & Condo, S. Diuretic therapy in heart failure. G. Ital. Nefrol. 23, S74–S76 (2006).
  PubMed Google Scholar
• Kyllonen, M. S. et al. Localization of carbonic anhydrase XII to the basolateral membrane of H+-secreting cells of mouse and rat kidney. J. Histochem. Cytochem. 51, 1217–1224 (2003).
  PubMed Google Scholar
• Mincione, F. et al. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. Curr. Top. Med. Chem. 7, 849–854 (2007).
  CAS PubMed Google Scholar
• Sugrue, M. F. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Retin. Eye Res. 19, 87–112 (2000).
  CAS PubMed Google Scholar
• Scozzafava, A. et al. Carbonic anhydrase inhibitors. Part 74. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. 42, 2641–2650 (1999).
  CAS PubMed Google Scholar
• Scozzafava, A. et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J. Med. Chem. 42, 3690–3700 (1999).
  CAS PubMed Google Scholar
• Ilies, M. et al. Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg. Med. Chem. 8, 2145–2155 (2000).
  CAS PubMed Google Scholar
• Scozzafava, A. et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem. 43, 4542–4551 (2000).
  CAS PubMed Google Scholar
• Scozzafava, A. et al. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J. Med. Chem. 45, 1466–1476 (2002).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: _N_-(p-sulfamoylphenyl)-a-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett. 14, 225–229 (2004).
  CAS PubMed Google Scholar
• Cox, S. N. et al. Treatment of chronic macular edema with acetazolamide. Arch. Ophthalmol. 106, 1190–1195 (1988).
  CAS PubMed Google Scholar
• Gao, B. B. et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Med. 13, 181–188 (2007). An important study showing the involvement of CA I (an orphan target) in retinal and cerebral disease.
  CAS PubMed Google Scholar
• Supuran, C. T. et al. in Carbonic Anhydrase – Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 67–147 (CRC, Boca Raton, 2004). A comprehensive review of the development of sulphonamdes as CAIs.
  Google Scholar
• Maren, T. H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma 4, 49–62 (1995).
  CAS PubMed Google Scholar
• Innocenti, A. et al. Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg. Med. Chem. Lett. 15, 1149–1154 (2005).
  CAS PubMed Google Scholar
• Liao, S. Y. et al. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CA XII) in glaucoma. J. Med. Genet. 40, 257–261 (2003).
  CAS PubMed PubMed Central Google Scholar
• Supuran, C. T. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 13, 1545–1550 (2003).
  CAS Google Scholar
• Casini, A. et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 13, 841–845 (2003).
  CAS PubMed Google Scholar
• Picard, F. et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obesity Res. 8, 656–663 (2000).
  CAS Google Scholar
• De Simone, G. et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15, 2315–2320 (2005).
  CAS PubMed Google Scholar
• Gadde, K. M. et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289, 1820–1825 (2003).
  CAS PubMed Google Scholar
• Maxwell, P. H., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
  CAS PubMed Google Scholar
• Pastorekova, S. & Pastorek, J. in Carbonic Anhydrase — Its Inhibitors and Activators (eds Supuran, C. T., Scozzafava, A. & Conway, J.) 255–281 (CRC, Boca Raton, 2004).
  Google Scholar
• Semenza, G. L. Hypoxia and cancer. Cancer Metastasis Rev. 26, 223–224 (2007).
  CAS PubMed Google Scholar
• Brahimi-Horn, M. C. & Pouyssegur, J. Oxygen, a source of life and stress. FEBS Lett. 581, 3582–3591 (2007).
  CAS PubMed Google Scholar
• Jaakkola, P. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
  CAS PubMed Google Scholar
• Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975–978 (2002).
  CAS PubMed Google Scholar
• Ratcliffe, P. J. et al. Targeting tumors through the HIF system. Nature Med. 6, 1315–1316 (2000).
  CAS PubMed Google Scholar
• Trastour, C. et al. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 120, 1451–1458 (2007).
  CAS PubMed Google Scholar
• Pouyssegur, J. et al. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437–443 (2006).
  CAS PubMed Google Scholar
• Ord, J. J. et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J. Urol. 178, 677–682 (2007).
  PubMed Google Scholar
• Swietach, P. et al. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26, 299–310 (2007).
  CAS PubMed Google Scholar
• Hutchison, G. J. et al. Hypoxia-inducible factor 1-α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin. Cancer Res. 10, 8405–8412 (2004).
  CAS PubMed Google Scholar
• Sung, F. L. et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett. 253, 74–88 (2007).
  CAS PubMed Google Scholar
• Koukourakis, M. I. et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 67–71 (2004).
  CAS PubMed Google Scholar
• Potter, C. P. & Harris, A. L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 89, 2–7 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hussain, S. A. et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 96, 104–109 (2007).
  CAS PubMed PubMed Central Google Scholar
• Swinson, D. E. et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 21, 473–482 (2003).
  CAS PubMed Google Scholar
• Dorai, T. et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest. 24, 754–779 (2006).
  CAS PubMed Google Scholar
• Abbate, F. et al. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with a EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. 14, 231–234 (2004).
  CAS PubMed Google Scholar
• Di Fiore, A. et al. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related, cyclooxygenase II “selective” inhibitor celecoxib. Bioorg. Med. Chem. Lett. 16, 437–442 (2006).
  CAS PubMed Google Scholar
• Abbate, F. et al. Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. 14, 337–341 (2004).
  CAS PubMed Google Scholar
• Svastova, E. et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577, 439–445 (2004). A proof-of-concept study showing the involvement of CA IX in tumour acidification and its reversal by inhibition of the enzyme.
  CAS PubMed Google Scholar
• Cecchi, A. et al. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 48, 4834–4841 (2005).
  CAS PubMed Google Scholar
• Menchise, V. et al. Carbonic anhydrase inhibitors: Stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 48, 5721–5727 (2005).
  CAS PubMed Google Scholar
• Ilies, M. A., et al. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 46, 2187–2196 (2003).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. 46, 2197–2204 (2003).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. 46, 5471–5477 (2003).
  CAS PubMed Google Scholar
• Pastorekova, S. et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 14, 869–873 (2004).
  CAS PubMed Google Scholar
• Vullo, D. et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett. 14, 2351–2356 (2004).
  CAS PubMed Google Scholar
• Casey, J. R. et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 47, 2337–2347 (2004).
  CAS PubMed Google Scholar
• Supuran, C. T. et al. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev. Med. Chem. 4, 625–632 (2004).
  CAS PubMed Google Scholar
• Garaj, V. et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg. Med. Chem. Lett. 14, 5427–5433 (2004).
  CAS PubMed Google Scholar
• Innocenti, A. et al. Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J. Med. Chem. 47, 5224–5229 (2004).
  CAS PubMed Google Scholar
• Cecchi, A. et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett. 14, 5775–5780 (2004).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J. Med. Chem. 48, 2121–2125 (2005).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg. Med. Chem. Lett. 15, 579–584 (2005).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with _N_-hydroxysulfamides — a new zinc-binding function in the design of inhibitors. Bioorg. Med. Chem. Lett. 15, 2353–2358 (2005).
  CAS PubMed Google Scholar
• Winum, J. Y. et al. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett. 15, 3302–3306 (2005).
  CAS PubMed Google Scholar
• Thiry, A. et al. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem. 49, 2743–2749 (2006).
  CAS PubMed Google Scholar
• Wilkinson, B. L. et al. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by “click-tailing”. J. Med. Chem. 49, 6539–6548 (2006).
  CAS PubMed Google Scholar
• Wilkinson, B. L. et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked _O_-glycosides of benzene sulfonamides. J. Med. Chem. 50, 1651–1657 (2007).
  CAS PubMed Google Scholar
• Dubois, L. et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 83, 367–373 (2007).
  CAS PubMed Google Scholar
• Abbate, F. et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 14, 217–223 (2004).
  CAS PubMed Google Scholar
• Owa, T. et al. Array-based structure and gene expression relationship study of antitumor sulfonamides including _N_-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-benzenesulfonamide and _N_-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J. Med. Chem. 45, 4913–4922 (2002).
  CAS PubMed Google Scholar
• Owa, T. et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 42, 3789–3799 (1999). A study reporting the discovery of indisulam, an anticancer sulphonamide in clinical development.
  CAS PubMed Google Scholar
• Talbot, D. C. et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 13, 1816–1822 (2007).
  CAS PubMed Google Scholar
• Riihonen, R. et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone 40, 1021–1031 (2007).
  CAS PubMed Google Scholar
• Innocenti, A. et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. Bioorg. Med. Chem. Lett. 14, 4563–4567 (2004).
  CAS PubMed Google Scholar
• Zimmerman, S. A. et al. Carbonic anhydrase inhibitors. Inhibition of the prokariotic b and g-class enzymes from Archaea with sulfonamides. Bioorg. Med. Chem. Lett. 14, 6001–6006 (2004). First study showing that β- and γ-CA enzymes are also inhibited by sulphonamides.
  CAS PubMed Google Scholar
• Zimmerman, S. A., Ferry, J. G. & Supuran C. T. Inhibition of the archaeal β-Class (Cab) and γ-Class (Cam) carbonic anhydrases. Curr. Top. Med. Chem. 7, 901–908 (2007).
  CAS PubMed Google Scholar
• Sun, M. K. & Alkon, D. L. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J. Pharmacol. Exp. Ther. 297, 961–967 (2001).
  CAS PubMed Google Scholar
• Supuran, C. T. & Clare, B. W. Carbonic anhydrase activators. Part 3. Structure–activity correlations for a series of isozyme II activators. J. Pharm. Sci. 83, 768–773 (1994).
  PubMed Google Scholar
• Supuran, C. T. & Scozzafava, A. Carbonic anhydrase activators: amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators. Bioorg. Med. Chem. 7, 2915–2923 (1999).
  CAS PubMed Google Scholar
• Scozzafava, A. & Supuran, C. T. Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. J. Med. Chem. 45, 284–291 (2002).
  CAS PubMed Google Scholar
• Ilies, M. et al. Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties. J. Med. Chem. 45, 504–510 (2002).
  CAS PubMed Google Scholar
• Scozzafava, A. & Supuran, C. T. Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg. Med. Chem. Lett. 12, 1177–1180 (2002).
  CAS PubMed Google Scholar
• Parkkila, S. et al. Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines. Bioorg. Med. Chem. Lett. 16, 3955–3959 (2006).
  CAS PubMed Google Scholar
• Temperini, C. et al. Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. Bioorg. Med. Chem. Lett. 16, 5152–5156 (2006). First X-ray crystallographic report of an activator of CA I, showing important differences in the activation mechanisms of CA I and II.
  CAS PubMed Google Scholar
• Nishimori, I. et al. Carbonic anhydrase activators: the first activation study of the human secretory isoform VI with amino acids and amines. Bioorg. Med. Chem. Lett. 17, 5351–5357 (2007).
  Google Scholar